COVID-19 outcomes in haemopoietic stem cell transplant recipients in Western Australia: the value of vaccination and antiviral therapy.
Jacques A J MalherbePeter A BoanDuncan PurtillMatthew WrightPaul CannellShane A GangatharanHasib SidiqiJulian P CooneyPublished in: Internal medicine journal (2024)
Coronavirus-19 (COVID-19) mortality rates among haemopoietic stem cell transplant (HSCT) patients are high, ranging between 20% and 40%. We prospectively evaluated the mortality outcomes of COVID-19 in Western Australian HSCT patients. A total of 32/492 (6.5%) HSCT recipients contracted COVID-19 during the study, of whom 30/32 (94%) developed mild or asymptomatic disease. Two allogeneic HSCT patients were hospitalised for severe COVID-19; one patient died. Stringent healthcare, social isolation practices, aggressive vaccination programmes and rapid access to COVID-19 antivirals may have promoted mild COVID-19 illness in Western Australian HSCT patients, resulting in one of the lowest COVID-19 mortality rates in HSCT recipients worldwide.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- stem cells
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- south africa
- respiratory syndrome coronavirus
- stem cell transplantation
- risk factors
- cardiovascular disease
- coronary artery disease
- social media
- quantum dots
- high dose
- insulin resistance
- skeletal muscle
- health information
- kidney transplantation
- replacement therapy